| Dr William Douglas Thomas Ii, DO | |
|
901 Plantation Rd Ste 1, Blacksburg, VA 24060-3880 | |
| (540) 951-0352 | |
| (540) 951-7724 |
| Full Name | Dr William Douglas Thomas Ii |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 17 Years |
| Location | 901 Plantation Rd Ste 1, Blacksburg, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386811073 | NPI | - | NPPES |
| 1386811073 | Medicaid | VA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carilion New River Valley Medical Center | Christiansburg, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carilion Healthcare Corporation | 5890607253 | 408 |
News Archive
Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.
Pregnant women who gain excessive or even appropriate weight, according to current guidelines, are four times more likely than women who gain inadequate weight to have a baby who becomes overweight in early childhood.
When a proposal to encourage end-of-life planning touched off a political storm over "death panels," Democrats dropped it from legislation to overhaul the health care system. But the Obama administration will achieve the same goal by regulation, starting Jan. 1. Under the new policy, outlined in a Medicare regulation, the government will pay doctors who advise patients on options for end-of-life care, which may include advance directives to forgo aggressive life-sustaining treatment (Pear, 12/25).
A study led by Xiaoching Li, PhD, at the LSU Health Sciences Center New Orleans Neuroscience Center of Excellence, has shown for the first time how two tiny molecules regulate a gene implicated in speech and language impairments as well as autism disorders, and that social context of vocal behavior governs their function.
› Verified 3 days ago
| Entity Name | Carilion Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447206370 PECOS PAC ID: 5890607253 Enrollment ID: O20031106000273 |
News Archive
Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.
Pregnant women who gain excessive or even appropriate weight, according to current guidelines, are four times more likely than women who gain inadequate weight to have a baby who becomes overweight in early childhood.
When a proposal to encourage end-of-life planning touched off a political storm over "death panels," Democrats dropped it from legislation to overhaul the health care system. But the Obama administration will achieve the same goal by regulation, starting Jan. 1. Under the new policy, outlined in a Medicare regulation, the government will pay doctors who advise patients on options for end-of-life care, which may include advance directives to forgo aggressive life-sustaining treatment (Pear, 12/25).
A study led by Xiaoching Li, PhD, at the LSU Health Sciences Center New Orleans Neuroscience Center of Excellence, has shown for the first time how two tiny molecules regulate a gene implicated in speech and language impairments as well as autism disorders, and that social context of vocal behavior governs their function.
› Verified 3 days ago
| Entity Name | Carilion Rockbridge Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174636021 PECOS PAC ID: 4789658261 Enrollment ID: O20040820000838 |
News Archive
Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.
Pregnant women who gain excessive or even appropriate weight, according to current guidelines, are four times more likely than women who gain inadequate weight to have a baby who becomes overweight in early childhood.
When a proposal to encourage end-of-life planning touched off a political storm over "death panels," Democrats dropped it from legislation to overhaul the health care system. But the Obama administration will achieve the same goal by regulation, starting Jan. 1. Under the new policy, outlined in a Medicare regulation, the government will pay doctors who advise patients on options for end-of-life care, which may include advance directives to forgo aggressive life-sustaining treatment (Pear, 12/25).
A study led by Xiaoching Li, PhD, at the LSU Health Sciences Center New Orleans Neuroscience Center of Excellence, has shown for the first time how two tiny molecules regulate a gene implicated in speech and language impairments as well as autism disorders, and that social context of vocal behavior governs their function.
› Verified 3 days ago
| Entity Name | Carilion Giles Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194718304 PECOS PAC ID: 3678670221 Enrollment ID: O20070516000487 |
News Archive
Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.
Pregnant women who gain excessive or even appropriate weight, according to current guidelines, are four times more likely than women who gain inadequate weight to have a baby who becomes overweight in early childhood.
When a proposal to encourage end-of-life planning touched off a political storm over "death panels," Democrats dropped it from legislation to overhaul the health care system. But the Obama administration will achieve the same goal by regulation, starting Jan. 1. Under the new policy, outlined in a Medicare regulation, the government will pay doctors who advise patients on options for end-of-life care, which may include advance directives to forgo aggressive life-sustaining treatment (Pear, 12/25).
A study led by Xiaoching Li, PhD, at the LSU Health Sciences Center New Orleans Neuroscience Center of Excellence, has shown for the first time how two tiny molecules regulate a gene implicated in speech and language impairments as well as autism disorders, and that social context of vocal behavior governs their function.
› Verified 3 days ago
| Entity Name | Colliver Sports & Spine Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447545751 PECOS PAC ID: 2264603026 Enrollment ID: O20110927000817 |
News Archive
Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.
Pregnant women who gain excessive or even appropriate weight, according to current guidelines, are four times more likely than women who gain inadequate weight to have a baby who becomes overweight in early childhood.
When a proposal to encourage end-of-life planning touched off a political storm over "death panels," Democrats dropped it from legislation to overhaul the health care system. But the Obama administration will achieve the same goal by regulation, starting Jan. 1. Under the new policy, outlined in a Medicare regulation, the government will pay doctors who advise patients on options for end-of-life care, which may include advance directives to forgo aggressive life-sustaining treatment (Pear, 12/25).
A study led by Xiaoching Li, PhD, at the LSU Health Sciences Center New Orleans Neuroscience Center of Excellence, has shown for the first time how two tiny molecules regulate a gene implicated in speech and language impairments as well as autism disorders, and that social context of vocal behavior governs their function.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William Douglas Thomas Ii, DO 213 S Jefferson St Ste 1006, Roanoke, VA 24011-1713 Ph: (154) 022-4535 | Dr William Douglas Thomas Ii, DO 901 Plantation Rd Ste 1, Blacksburg, VA 24060-3880 Ph: (540) 951-0352 |
News Archive
Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.
Pregnant women who gain excessive or even appropriate weight, according to current guidelines, are four times more likely than women who gain inadequate weight to have a baby who becomes overweight in early childhood.
When a proposal to encourage end-of-life planning touched off a political storm over "death panels," Democrats dropped it from legislation to overhaul the health care system. But the Obama administration will achieve the same goal by regulation, starting Jan. 1. Under the new policy, outlined in a Medicare regulation, the government will pay doctors who advise patients on options for end-of-life care, which may include advance directives to forgo aggressive life-sustaining treatment (Pear, 12/25).
A study led by Xiaoching Li, PhD, at the LSU Health Sciences Center New Orleans Neuroscience Center of Excellence, has shown for the first time how two tiny molecules regulate a gene implicated in speech and language impairments as well as autism disorders, and that social context of vocal behavior governs their function.
› Verified 3 days ago
Dr. Michael Howard Clary, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3700 S Main St, Suite A, Blacksburg, VA 24060 Phone: 540-443-7187 Fax: 540-443-7182 | |
Mrs. Holli Dezaun Waller, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3700 South Main Street, Blacksburg, VA 24060 Phone: 540-953-5445 Fax: 540-953-5453 | |
Jason Le, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 1691 Innovation Dr Ste 2100, Blacksburg, VA 24060 Phone: 540-232-8405 | |
David Woodson, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 215 Gilbert St, Blacksburg, VA 24060 Phone: 540-961-8040 Fax: 540-961-9466 | |
Pete A. Guerra, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2401 S Main St Ste D, Blacksburg, VA 24060 Phone: 540-418-1910 | |
Crystal Downer, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3700 S Main St Ste 1a, Blacksburg, VA 24060 Phone: 540-443-7180 Fax: 540-443-3725 | |
Andrea Lynn Hall, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1645 North Main Street, Blacksburg, VA 24060 Phone: 540-552-1246 Fax: 540-552-1247 |